Arbutus Biopharma (LTS:0SGC) Institutional Ownership: 30.13% (As of Jul. 27, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0SGC Arbutus Biopharma Corp LTS:0SGC
51 GF Score
Price $3.32
GF Value $38.35
! 5 Warning Signs
View Full Analysis

What is Arbutus Biopharma Institutional Ownership?

Arbutus Biopharma LTS:0SGC 51 Institutional Ownership is 30.13% as of Jul. 27, 2026. GuruFocus rates LTS:0SGC with a GF Score™ of 51/100 and a GF Value™ of $38.35. The stock has 5 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Arbutus Biopharma's institutional ownership is 30.13%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Arbutus Biopharma's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Arbutus Biopharma's Float Percentage Of Total Shares Outstanding is 67.22%.

Arbutus Biopharma Institutional Ownership Historical Data

* Premium members only.

The historical data trend for Arbutus Biopharma's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Arbutus Biopharma Institutional Ownership Chart

Arbutus Biopharma Historical Data

The historical data trend for Arbutus Biopharma can be seen below:

2025-09-30 2025-10-31 2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30
Institutional Ownership 28.99 28.98 29.09 29.18 29.02 29.21 28.46 28.43 28.35 30.13
LTS:0SGC
51GF Score
Arbutus Biopharma Corp LTS:0SGC
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Arbutus Biopharma Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 30.13% mean?
Arbutus Biopharma (LTS:0SGC) has a Institutional Ownership of 30.13% as of Jul. 27, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Arbutus Biopharma and its competitors.
Is Arbutus Biopharma's Institutional Ownership too high?
Arbutus Biopharma's current Institutional Ownership is 30.13%. Overall, Arbutus Biopharma has a GF Score™ of 51/100, reflecting its overall financial health beyond just this single metric.
How does Arbutus Biopharma's Institutional Ownership compare to TBPH and ANNX?
Arbutus Biopharma's Institutional Ownership of 30.13% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Biotechnology company?
A good Institutional Ownership depends on the Biotechnology industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Arbutus Biopharma and its competitors. Arbutus Biopharma's current Institutional Ownership is 30.13%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arbutus Biopharma stock overvalued right now?
Arbutus Biopharma (LTS:0SGC) has a current Institutional Ownership of 30.13%. The stock's GF Value™ is $38.35, compared to a current price of $3.32 — trading 91.3% below its estimated fair value. The current Institutional Ownership is 30.13%. Arbutus Biopharma's overall GF Score™ is 51/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For Arbutus Biopharma (LTS:0SGC), the current Institutional Ownership is 30.13% as of Jul. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Arbutus Biopharma (LTS:0SGC) Overvalued in 2026?

Based on GuruFocus' analysis, Arbutus Biopharma stock appears to be undervalued. The current stock price of $3.32 is trading 91.3% below its estimated GF Value™ of $38.35.

Key valuation signals for LTS:0SGC:

  • Institutional Ownership: 30.13%
  • GF Value™: $38.35 vs. price of $3.32 (91.3% below fair value)
  • GF Score™: 51/100 with 5 warning signs

No single metric tells the full story. See the LTS:0SGC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Arbutus Biopharma Business Description

Other Exchanges ABUS:USAI9DN:Germany
Address 701 Veterans Circle, Warminster, PA, USA, 18974
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.
51GF Score

Get the complete analysis for LTS:0SGC

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.32
Price
$38.35
GF Value